Skip to main content
Top
Published in: Diabetologia 3/2018

01-03-2018 | Review

Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach

Authors: Giuseppe Mancia, Guido Grassi

Published in: Diabetologia | Issue 3/2018

Login to get access

Abstract

When associated with high blood pressure, type 2 diabetes mellitus is characterised by a high risk of adverse cardiovascular (CV) and renal outcomes. However, both can be effectively reduced by antihypertensive treatment. Current guidelines on the treatment of hypertension emphasize the need to effectively treat high blood pressure in diabetic individuals, but their recommendations differ in terms of the optimal target blood pressure value to aim for in order to maximise CV and renal protection. In some guidelines the recommended target blood pressure values are <140/90 mmHg (systolic/diastolic), whereas in others, blood pressure values close or even less than 130/80 mmHg are recommended. This paper will discuss the evidence for and against a conservative or more aggressive blood pressure target for treated diabetic hypertensive individuals based on the evidence provided by randomised trials, trial meta-analyses and large observational studies. Based on the available evidence, it appears that blood pressure targets will probably have to be lower than <140/90 mmHg, and that values approaching 130/80 mmHg should be recommended. However, evidence in favour of even lower systolic values, i.e. <130 mmHg, is limited and is definitively against a reduction to <120 mmHg.
Appendix
Available only for authorised users
Literature
1.
go back to reference UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713CrossRefPubMedCentral UK Prospective Diabetes Study Group (1998) Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ 317:703–713CrossRefPubMedCentral
2.
go back to reference Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed Emdin CA, Rahimi K, Neal B, Callender T, Perkovic V, Patel A (2015) Blood pressure lowering in type 2 diabetes. A systematic review and meta-analysis. JAMA 313:603–615CrossRefPubMed
3.
go back to reference Bangalore S, Kumar S, Lobach I, Messerli FH (2011) Blood pressure targets in patients with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesan random-effects meta-analyses of randomized trials. Circulation 123:2799–2810CrossRefPubMed Bangalore S, Kumar S, Lobach I, Messerli FH (2011) Blood pressure targets in patients with type 2 diabetes mellitus/impaired fasting glucose: observations from traditional and bayesan random-effects meta-analyses of randomized trials. Circulation 123:2799–2810CrossRefPubMed
4.
go back to reference Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and metanalyses. BMJ 24:352 i717 Brunström M, Carlberg B (2016) Effect of antihypertensive treatment at different blood pressure levels in patients with diabetes mellitus: systematic review and metanalyses. BMJ 24:352 i717
5.
go back to reference Thomopoulos C, Parati G, Zanchetti A (2017) Effects of blood pressure lowering treatment on outcome incidence in hypertension: 10. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944CrossRefPubMed Thomopoulos C, Parati G, Zanchetti A (2017) Effects of blood pressure lowering treatment on outcome incidence in hypertension: 10. Should blood pressure management differ in hypertensive patients with and without diabetes mellitus? Overview and meta-analyses of randomized trials. J Hypertens 35:922–944CrossRefPubMed
6.
go back to reference Reboldi G, Gentile G, Angeli F et al (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29:1253–1269CrossRefPubMed Reboldi G, Gentile G, Angeli F et al (2011) Effects of intensive blood pressure reduction on myocardial infarction and stroke in diabetes: a meta-analysis in 73,913 patients. J Hypertens 29:1253–1269CrossRefPubMed
7.
go back to reference American Diabetes Association (2012) Standards of medical care in diabetes – 2012. Diabetes Care 35(Suppl 1):s11–s63 American Diabetes Association (2012) Standards of medical care in diabetes – 2012. Diabetes Care 35(Suppl 1):s11–s63
8.
go back to reference Mancia G, Narkiewicz K, Redón J et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 31:1281–1357CrossRefPubMed Mancia G, Narkiewicz K, Redón J et al (2013) 2013 ESH/ESC guidelines for the management of arterial hypertension. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and the European Society of Cardiology (ESC). J Hypertens 31:1281–1357CrossRefPubMed
9.
go back to reference James PA, Oparil S, Carter B et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA 311:507–520CrossRefPubMed James PA, Oparil S, Carter B et al (2014) 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the eighth Joint National Committee (JNC 8). JAMA 311:507–520CrossRefPubMed
10.
go back to reference American Diabetes Association (2016) Standards of medical care in diabetes – 2016. Diabetes Care 39(Suppl 1):s1–s112 American Diabetes Association (2016) Standards of medical care in diabetes – 2016. Diabetes Care 39(Suppl 1):s1–s112
11.
go back to reference Rydén L, Grant PJ, Anker SD et al (2014) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087 Rydén L, Grant PJ, Anker SD et al (2014) ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes and cardiovascular diseases of the European Society of Cardiology(ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD). Eur Heart J 34:3035–3087
12.
go back to reference Giannattasio C, Failla M, Piperno A et al (1999) Early impairment of large artery structure and function in type 1 diabetes mellitus. Diabetologia 42:987–984CrossRefPubMed Giannattasio C, Failla M, Piperno A et al (1999) Early impairment of large artery structure and function in type 1 diabetes mellitus. Diabetologia 42:987–984CrossRefPubMed
13.
go back to reference Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over periheral arteries in type 2 diabetes. Diabetes 52:448–453CrossRefPubMed Kimoto E, Shoji T, Shinohara K et al (2003) Preferential stiffening of central over periheral arteries in type 2 diabetes. Diabetes 52:448–453CrossRefPubMed
14.
go back to reference Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187CrossRefPubMed Mancia G, De Backer G, Dominiczak A et al (2007) 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). J Hypertens 25:1105–1187CrossRefPubMed
15.
go back to reference Zanchetti A, Grassi G, Mancia G (2009) When should antihypertensive drug treatment be initiated and what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 27:923–934CrossRefPubMed Zanchetti A, Grassi G, Mancia G (2009) When should antihypertensive drug treatment be initiated and what levels should systolic blood pressure be lowered? A critical reappraisal. J Hypertens 27:923–934CrossRefPubMed
16.
go back to reference Mancia G, Laurent S, Agabiti-Rosei E et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens 27:2121–2158CrossRefPubMed Mancia G, Laurent S, Agabiti-Rosei E et al (2009) Reappraisal of European guidelines on hypertension management: a European Society of Hypertension task force document. J Hypertens 27:2121–2158CrossRefPubMed
17.
go back to reference Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097CrossRefPubMed Schrier RW, Estacio RO, Esler A, Mehler P (2002) Effects of aggressive blood pressure control in normotensive type 2 diabetic patients on albuminuria, retinopathy and strokes. Kidney Int 61:1086–1097CrossRefPubMed
18.
go back to reference Patel A for the ADVANCE Collaborative Group (2007) Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRef Patel A for the ADVANCE Collaborative Group (2007) Effects of fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 370:829–840CrossRef
19.
go back to reference Redon J, Mancia G, Sleight P et al (2012) Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET. J Am Coll Cardiol 59:74–83CrossRefPubMed Redon J, Mancia G, Sleight P et al (2012) Safety and efficacy of low blood pressures among patients with diabetes: subgroup analyses from the ONTARGET. J Am Coll Cardiol 59:74–83CrossRefPubMed
20.
go back to reference Mancia G, Kjeldsen SE, Zappe DH et al (2016) Cardiovascular outcomes at different on-treatment blood pressure in the hypertensive patients of the VALUE trial. Eur Heart J 37:955–964CrossRefPubMed Mancia G, Kjeldsen SE, Zappe DH et al (2016) Cardiovascular outcomes at different on-treatment blood pressure in the hypertensive patients of the VALUE trial. Eur Heart J 37:955–964CrossRefPubMed
21.
go back to reference Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61–68CrossRefPubMedPubMedCentral Cooper-DeHoff RM, Gong Y, Handberg EM et al (2010) Tight blood pressure control and cardiovascular outcomes among hypertensive patients with diabetes and coronary artery disease. JAMA 304:61–68CrossRefPubMedPubMedCentral
22.
go back to reference Jamerson K, Weber MA, Bakris GL et al (2008) Benazepril plus amlodipine or hydrochlothiazide for hypertension in high risk patients. N Engl J Med 359:2417–2428CrossRefPubMed Jamerson K, Weber MA, Bakris GL et al (2008) Benazepril plus amlodipine or hydrochlothiazide for hypertension in high risk patients. N Engl J Med 359:2417–2428CrossRefPubMed
23.
go back to reference Mancia G, Grassi G (2014) Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63:29–36CrossRefPubMed Mancia G, Grassi G (2014) Aggressive blood pressure lowering is dangerous: the J-curve: pro side of the arguement. Hypertension 63:29–36CrossRefPubMed
24.
go back to reference ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRef ACCORD Study Group (2010) Effects of intensive blood-pressure control in type 2 diabetes mellitus. N Engl J Med 362:1575–1585CrossRef
26.
go back to reference Odden MC, McClure LA, Sawaya BP et al (2016) Achieved blood pressure and outcomes in the Secondary prevention of Small Subcortical Strokes Trial. Hypertension 67:63–69CrossRefPubMed Odden MC, McClure LA, Sawaya BP et al (2016) Achieved blood pressure and outcomes in the Secondary prevention of Small Subcortical Strokes Trial. Hypertension 67:63–69CrossRefPubMed
27.
go back to reference PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood pressure lowering regimen among individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041CrossRef PROGRESS Collaborative Group (2001) Randomised trial of a perindopril-based blood pressure lowering regimen among individuals with previous stroke or transient ischaemic attack. Lancet 358:1033–1041CrossRef
28.
go back to reference Arima H, Anderson C, Omae T et al (2014) Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol Neurosurg Psychiatry 85:1264–1265CrossRef Arima H, Anderson C, Omae T et al (2014) Degree of blood pressure reduction and recurrent stroke: the PROGRESS trial. J Neurol Neurosurg Psychiatry 85:1264–1265CrossRef
29.
go back to reference Margolis KL, O’Connor PJ, Morgan TT et al (2014) Outcomes of combined risk factor management strategies in type 2 diabetes. The ACCORD randomized trial. Diabetes Care 37:1721–1728CrossRefPubMedPubMedCentral Margolis KL, O’Connor PJ, Morgan TT et al (2014) Outcomes of combined risk factor management strategies in type 2 diabetes. The ACCORD randomized trial. Diabetes Care 37:1721–1728CrossRefPubMedPubMedCentral
30.
go back to reference Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403CrossRefPubMed Kelly TN, Bazzano LA, Fonseca VA, Thethi TK, Reynolds K, He J (2009) Systematic review: glucose control and cardiovascular disease in type 2 diabetes. Ann Intern Med 151:394–403CrossRefPubMed
32.
go back to reference Weber MA, Bakris GL, Hester A et al (2013) Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med 126:501–508CrossRefPubMed Weber MA, Bakris GL, Hester A et al (2013) Systolic blood pressure and cardiovascular outcomes during treatment of hypertension. Am J Med 126:501–508CrossRefPubMed
33.
go back to reference Peterson JC, Adler S, Burkart JM et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Study. Ann Intern Med 123:754–762CrossRefPubMed Peterson JC, Adler S, Burkart JM et al (1995) Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Study. Ann Intern Med 123:754–762CrossRefPubMed
34.
go back to reference Jackson CE, Solomon SD, Gerstein HC et al (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550CrossRefPubMed Jackson CE, Solomon SD, Gerstein HC et al (2009) Albuminuria in chronic heart failure: prevalence and prognostic importance. Lancet 374:543–550CrossRefPubMed
35.
go back to reference Ishani A, Grandits GA, Grimm RH et al (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial. J Am Soc Nephrol 17:1444–1452CrossRefPubMed Ishani A, Grandits GA, Grimm RH et al (2006) Association of single measurements of dipstick proteinuria, estimated glomerular filtration rate and hematocrit with 25-year incidence of end-stage renal disease in the Multiple Risk Factor Intervention Trial. J Am Soc Nephrol 17:1444–1452CrossRefPubMed
36.
go back to reference Schmieder RE, Schutte R, Schumacher H et al (2014) Mortality and morbidity in relation to change in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET AND TRANSCEND studies. Diabetologia 57:2019–2029CrossRefPubMed Schmieder RE, Schutte R, Schumacher H et al (2014) Mortality and morbidity in relation to change in albuminuria, glucose status and systolic blood pressure: an analysis of the ONTARGET AND TRANSCEND studies. Diabetologia 57:2019–2029CrossRefPubMed
37.
go back to reference Schmieder RE, Mann JF, Schumacher H et al (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22:1353–1364CrossRefPubMedPubMedCentral Schmieder RE, Mann JF, Schumacher H et al (2011) Changes in albuminuria predict mortality and morbidity in patients with vascular disease. J Am Soc Nephrol 22:1353–1364CrossRefPubMedPubMedCentral
38.
go back to reference Pascual JM, Rodilla E, Costa JA, Garcia-Escrich M, Gonzales C, Redon J (2014) Prognostic value of miscroalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 64:1169–1174CrossRef Pascual JM, Rodilla E, Costa JA, Garcia-Escrich M, Gonzales C, Redon J (2014) Prognostic value of miscroalbuminuria during antihypertensive treatment in essential hypertension. Hypertension 64:1169–1174CrossRef
39.
go back to reference Ismail-Beigi F, Craven TE, O’Connor PJ et al (2012) Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type diabetic patients. Kidney Int 81:586–594CrossRefPubMed Ismail-Beigi F, Craven TE, O’Connor PJ et al (2012) Combined intensive blood pressure and glycemic control does not produce an additive benefit on microvascular outcomes in type diabetic patients. Kidney Int 81:586–594CrossRefPubMed
40.
go back to reference Parving HH, Brenner BM, McMurray JJ et al (2012) Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2201–2213CrossRef Parving HH, Brenner BM, McMurray JJ et al (2012) Cardiorenal endpoints in a trial of aliskiren for type 2 diabetes. N Engl J Med 367:2201–2213CrossRef
41.
go back to reference Haller H, Ito S, Izzo JL et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med 364:907–917CrossRefPubMed Haller H, Ito S, Izzo JL et al (2011) Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. New Engl J Med 364:907–917CrossRefPubMed
42.
go back to reference Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762CrossRefPubMed Hansson L, Zanchetti A, Carruthers SG et al (1998) Effects of intensive blood-pressure lowering and low-dose aspirin in patients with hypertension: principal results of the Hypertension Optimal Treatment (HOT) randomised trial. Lancet 351:1755–1762CrossRefPubMed
43.
go back to reference Frattola A, Parati G, Gamba P et al (1997) Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 40:1470–1475CrossRefPubMed Frattola A, Parati G, Gamba P et al (1997) Time and frequency domain estimates of spontaneous baroreflex sensitivity provide early detection of autonomic dysfunction in diabetes mellitus. Diabetologia 40:1470–1475CrossRefPubMed
44.
go back to reference Whelton PK, Carey RM, Aronow WS et al (2017) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. https://doi.org/10.1016/j.jacc.2017.11.006 Whelton PK, Carey RM, Aronow WS et al (2017) 2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: a report of the American College of Cardiology/American Heart Association Task Force on clinical practice guidelines. J Am Coll Cardiol. https://​doi.​org/​10.​1016/​j.​jacc.​2017.​11.​006
46.
go back to reference Arima H, Anderson C, Omae T et al (2012) Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke 43:1675–1677CrossRefPubMed Arima H, Anderson C, Omae T et al (2012) Effects of blood pressure lowering on intracranial and extracranial bleeding in patients on antithrombotic therapy: the PROGRESS trial. Stroke 43:1675–1677CrossRefPubMed
47.
go back to reference Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967CrossRefPubMed Ettehad D, Emdin CA, Kiran A et al (2016) Blood pressure lowering for prevention of cardiovascular disease and death: a systematic review and meta-analysis. Lancet 387:957–967CrossRefPubMed
48.
go back to reference Zanchetti A, Thomopoulos C, Parati G (2015) Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 116:1058–1073CrossRefPubMed Zanchetti A, Thomopoulos C, Parati G (2015) Randomized controlled trials of blood pressure lowering in hypertension: a critical reappraisal. Circ Res 116:1058–1073CrossRefPubMed
49.
go back to reference Mancia G, Grassi G (2002) Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20:1461–1464CrossRefPubMed Mancia G, Grassi G (2002) Systolic and diastolic blood pressure control in antihypertensive drug trials. J Hypertens 20:1461–1464CrossRefPubMed
50.
go back to reference Ambrosioni E, Leonetti G, Pessina A, Rappelli A, Trimarco B, Zanchetti A (2000) Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens 18:1691–1699CrossRefPubMed Ambrosioni E, Leonetti G, Pessina A, Rappelli A, Trimarco B, Zanchetti A (2000) Patterns of hypertension management in Italy: results of a pharmacoepidemiological survey on antihypertensive therapy. J Hypertens 18:1691–1699CrossRefPubMed
51.
go back to reference Thomopoulos C, Parati G, Zanchetti A (2016) Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs discontinuations because of adverse events-meta-analisys of randomized trials. J Hypertens 34:1451–1463CrossRefPubMed Thomopoulos C, Parati G, Zanchetti A (2016) Effects of blood pressure lowering treatment in hypertension: 8. Outcome reductions vs discontinuations because of adverse events-meta-analisys of randomized trials. J Hypertens 34:1451–1463CrossRefPubMed
52.
go back to reference Hirakawa Y, Arima H, Webster R et al (2016) Risk associated with permanent discontinuation of blood pressure lowering medications in patients with type 2 diabetes. J Hypertens 34:781–787CrossRefPubMed Hirakawa Y, Arima H, Webster R et al (2016) Risk associated with permanent discontinuation of blood pressure lowering medications in patients with type 2 diabetes. J Hypertens 34:781–787CrossRefPubMed
Metadata
Title
Blood pressure targets in type 2 diabetes. Evidence against or in favour of an aggressive approach
Authors
Giuseppe Mancia
Guido Grassi
Publication date
01-03-2018
Publisher
Springer Berlin Heidelberg
Published in
Diabetologia / Issue 3/2018
Print ISSN: 0012-186X
Electronic ISSN: 1432-0428
DOI
https://doi.org/10.1007/s00125-017-4537-3

Other articles of this Issue 3/2018

Diabetologia 3/2018 Go to the issue

Up front

Up front